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GenomicsActivated ﬁbroblasts are the central effector cells of the progressive ﬁbrotic process in idiopathic pulmonary
ﬁbrosis (IPF). Characterizing the genomic phenotype of isolated ﬁbroblasts is essential to understanding IPF
pathogenesis. Comparing the genomic phenotype of non-cultured pulmonary ﬁbroblasts from advanced IPF
patients' and normal lungs revealed novel genes, biological processes and concomitant pathways previously
unreported in IPF ﬁbroblasts. We demonstrate altered expression in proteasomal constituents, ubiquitina-
tion-mediators, Wnt, apoptosis and vitamin metabolic pathways and cell cycle regulators, suggestive of loss
of cellular homeostasis. Speciﬁcally, FBXO32, CXCL14, BDKRB1 and NMNAT1 were up-regulated, while RARA
and CDKN2D were down-regulated. Paradoxically, pro-apoptotic inducers TNFSF10, BAX and CASP6 were also
found to be increased. This comprehensive description of altered gene expression in isolated IPF ﬁbroblasts
underscores the complex biological processes characteristic of IPF and may provide a foundation for future
research into this devastating disease.7, Manassas, VA 20110, USA.
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is a fatal form of interstitial
lung disease (ILD) of unknown etiology, with an associated median
survival time of approximately 3 to 5 years from the time of diagnosis
[1]. There is no effective medical treatment or cure for IPF. The
purported effector cells of this devastating disease are the ﬁbroblasts,
predominantly evident in distinct ﬁbrotic foci in the diseased lung.
These activated ﬁbroblasts are largely felt to be responsible for the
production of the extracellular matrix (ECM), which forms the nidus
for subsequent ﬁbrosis with the resulting pathological, radiographic
and clinical sequelae that characterize the disease [2].
The purported pivotal role of the pulmonary ﬁbroblast in the
pathophysiology of IPF and the absence of effective therapies
underscore the necessity for a thorough molecular characterization
of this cell. This will enable a better understanding of the etiology
and triggers of this disease and guide potential therapeutic
strategies. To date there are no high through-put genomic analysis
studies that speciﬁcally characterize global expression changes ofthis cell in isolation prior to in vitro propagation, or in comparison to
its normal ﬁbroblast counterpart. Thus far, studies have provided
useful insights into the global genomic proﬁle of the whole IPF lung.
Speciﬁcally, the genomic proﬁle of IPF whole lung tissue has been
compared to other ILDs, including hypersensitivity pneumonitis and
non-speciﬁc interstitial pneumonitis (NSIP) [3]. In addition, studies
have also investigated the differential gene expression in familial
versus sporadic IPF [4].
Therefore, in this study, we set out to characterize the genomic
proﬁle of non-cultured IPF ﬁbroblasts in isolation to characterize the
speciﬁc contribution of this cellular component to this disease.
Speciﬁcally, the gene expression proﬁles of IPF ﬁbroblasts were
compared to normal ﬁbroblasts, using an oligo-microarray represent-
ing 33,791 transcripts from the Ensembl Human Build (BI-35C)
including 22,169 unique genes (Operon's Human Oligo Set, version
4.0). This is the ﬁrst report of a direct comparative analysis of non-
cultured IPF ﬁbroblasts to non-cultured normal pulmonary ﬁbro-
blasts. The ﬁbroblasts used in this study were isolated immediately
post-lung explantation, and were not subjected to long-term in vitro
propagation. This immediate isolation therefore bypassed the ded-
ifferentiating effects of long-term tissue culture and preserved, as
closely as possible, the cells' in vivo phenotype.
Our investigation of the genomic aberrations of IPF ﬁbroblasts
gives insight into the biological processes that characterize this
disease. This comprehensive characterization of the ﬁbroblast's
135M.C. Emblom-Callahan et al. / Genomics 96 (2010) 134–145genotype will hopefully provide a platform and a roadmap for future
studies into the pathogenesis and treatment of this deadly disease.
Materials and methods
We performed a prospective, comparative gene expression
analysis of ﬁbroblasts isolated from the lung tissue of 12 patients
with advanced IPF and 6 normal controls (Table 1). IPF lung tissue
was obtained through Inova Fairfax Hospital (VA). All normal
control lungs were obtained through the Washington Regional
Transplant Community (WRTC). Statistical signiﬁcance for the
demographic values of the two groups was determined by unpaired
t-test using Graph Pad Prism 4.0 software. This study was approved
by the Inova Fairfax Hospital Internal Review Board and the George
Mason University Human Subject Review Board.
Specimen procurement/dissection
Both IPF and normal lungs were procured in the operating room
within minutes of explantation. To ensure a consistent and equiv-
alent comparison, we oriented each lung from the apex to base, and
isolated samples from four discrete regions: peripheral, central,
upper and lower.
Post-dissection processing
We isolated the ﬁbroblasts by differential binding after enzy-
matic dissociation as previously described in Wang [5]. Speciﬁcally,
all samples were dissected into 1–2 mm2 pieces at 4 °C in PBS and
subjected to enzymatic digestion in 0.4% collagenase P (Roche,
Indianapolis, IN) in complete media (Dulbecco Minimum Essential
Media (DMEM) containing 10% fetal bovine serum (FBS), penicillin
(100 I.U./mL), streptomycin (100 MCH/mL), amphotericin B
(0.25 M.C.G/mL) (P/S/A)) and 0.1% DNase1, ﬁnal concentration at
37 °C in a humidiﬁed 5% CO2 incubator for 2 h. The resulting di-
gested material was passed through a sterile ﬁne mesh to remove
undigested tissue, and cells were collected by centrifugation at
1000 g for 5 min. The pelleted cells were re-suspended in com-
plete media and seeded onto tissue culture treated plastic (glass
slides for immunocytochemistry) at 37 °C and 5% CO2 for 45 min. At
45 min the attached ﬁbroblast cells were washed vigorously with
sterile PBS and ﬂash frozen for RNA extraction or ﬁxed for
immunocytochemistry.
Morphology of cell populations
Morphological analysis was carried out by phase contrast light
microscopy. Non-cultured IPF and normal ﬁbroblasts were imaged at
the 45 min attachment time-point, post-isolation. After 120 h in vitro,Table 1
Demographics of IPF and normal donors.
Variable IPF patient
(n=12)
Normal
(n=6)
p-value
Age 60.9 (±7.2)
years
50.8 (±18.1)
years
0.12
Sex Male 7 3 0.75
Female 5 3
Smoking history
(no current smokers)
None 2 6 b0.01
Past 10 0
Race African American 2 2 0.45
Caucasian 10 4the morphological effect of long-term culture was observed and
recorded.
Identiﬁcation of cell populations
The ﬁbroblast identity of these cells was conﬁrmed by immuno-
cytochemistry both in the 45 min differential binding population
and this same population continued in long-term cell culture for
120 h. Positive control cells included A549 (epithelial, human),
microvascular endothelial cells (endothelial, human) and MD
(macrophage, human) (ATCC, Rockville, MD). Brieﬂy, ﬁxed cells
(50/50% Acetone/Methanol (v/v) at −20 °C) were blocked in
blocking buffer (BB) (1× PBS with 0.3% Triton-X 100 (1× PBST)
and 5% normal goat or donkey serum) for 30 min at room
temperature, followed by overnight incubation at 4 °C in BB
containing the primary antibodies as follows: anti-human
actin, alpha 2, smooth muscle, aorta (αSMA)(Abcam #Ab7817;
ﬁbroblast), anti-human cytokeratin 18 (K18)(AbCam #Ab668;
epithelial), anti-human CDllb (AbCam #Ab52478; monocyte/mac-
rophage) and anti-human Von Willebrand's Factor (Ab68545;
endothelial). The cells were then rinsed in 1×PBST (3×10 min)
and incubated with secondary antibody: goat anti-mouse conjugat-
ed with Texas red (AbCam #6787) or donkey anti-rabbit conjugated
with Texas red (AbCam #6799), for 2 h at room temperature. The
cells were then incubated with DAPI (5 mg/mL) in dimethylforma-
mide for 2 min, and ﬁnally mounted in 80/20% glycerol/PBS (v/v).
Immunoﬂuorescent images were captured using a Nikon C1
confocal system mounted on a Nikon Eclipse 90i microscope. Images
were processed using Nikon EX-C1 imaging software and Adobe
Photoshop 4.0.
To determine the percentage of positively stained cells, the total
number of cells was counted in 5 random ﬁelds in addition to the
total number of positive cells for each antibody and the percent
determined.
Microarray analysis
RNA was extracted using a Qiagen RNeasy kit (Qiagen, Valencia,
CA) and DNase was treated using DNase free (Ambion, Austin, TX).
The quality and quantity of the RNA was determined using RNA
6000 nanochips and an Agilent Bioanalyzer. For microarray analysis,
1 µg of RNA was ampliﬁed and amino-allylated using the Messa-
geAmp II aRNA kit (Ambion). All microarrays were carried out by
the Duke Institute for Genome Sciences and Policy, Microarray
Facility using HO36K human chip (Operon Human Oligo set V4), and
two color amino-allylated ampliﬁed RNAs: cy5 patient and normal
samples, and cy3 Stratagene human reference RNA.
All analyses of the resulting genepix ﬁles was carried out using
the TM4 software suite (ExpressConverter V1.0, MIDAS, MEV) and
normalized by locally weighted linear regression (lowess) [6,7].
Normalized, ﬁltered (percent ﬁlter cut-off 60%) data was statisti-
cally analyzed using statistical analysis of microarray (SAM) [8].
Data was independently conﬁrmed using Mann–Whitney Analysis
Benjamini–Hochberg step-up procedure (Data not shown). A ﬁnal
list of 1813 transcripts including 1480 unique genes was derived,
with a False Discovery Rate (FDR) set to 0%. Signiﬁcant transcripts
were then clustered by Euclidean distance hierarchical clustering
using average linkage.
MIAME compliance
The data discussed in this publication have been deposited
in NCBI's Gene Expression Omnibus in fulﬁllment of MIAME
compliance requirements and are accessible through the
following link: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token=bnwnzkcamugmkdq&acc=GSE17978.
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Quantitative real time reverse transcriptase polymerase
chain reaction (qRT-PCR)
The direction and fold change of representative genes identiﬁed
by microarray analysis was conﬁrmed by qRT-PCR. DNase treated
unampliﬁed RNA (1 µg) was reverse-transcribed to cDNA using an
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). qRT-PCR was
carried out using Quantifast SYBR Green PCR Kit (Qiagen). Primers
were selected de novo or from previous publications (Table 2), and
samples were carried out in triplicate and normalized to 18S
expression levels using the delta delta CT method [9].
Multiple criteria were used to select genes for expression con-
ﬁrmation. Genes associated with signiﬁcantly represented biological
processes were chosen including a selection of randomly chosen
genes to prevent investigator bias. A combination of genes that were
up-regulated as well as down-regulated, and genes whose expres-
sion changes showed higher magnitude of change as well as genes
with smaller expression changes were included.
Western analysis of protein levels
Total cellular protein was isolated from the non-cultured IPF
and normal ﬁbroblasts using RIPA buffer (Pierce, Rockford, IL),
with addition of mini-complete protease inhibitors (Roche). The
total protein concentration was determined using the Bradford
assay (Bio-Rad). For western analysis, 30 µg of total protein for
each sample was subjected to electrophoresis in a 4–12% Bis-Tris
gradient gel (Invitrogen, Carlsbad, CA). Transfer was carried out
using the iBLOT system (Invitrogen) and nitrocellulose membranes.
Owing to the documented instability of loading controls in pri-
mary lung tissue, to ensure equal loading, all lysates were sub-
jected to a) triplicate independent Bradford assay to ensure accurate
quantiﬁcation of protein concentration, b) Coomassie Blue staining
of gels to visualize and verify equivalent protein loading (Simply
Blue solution (Invitrogen)), and c) 1% Ponceau S staining (Sigma, St.
Louis, MO) of transfer membrane for total protein transferred.Table 2
qRT-PCR primers and amplicon lengths used to verify observed microarray expression chan
Gene symbol Forward primer
18S GATGGGCGGGGAAAATAG
BAX GGGTGGTTGGGTGAGACTC
CCNH TGTTCGGTGTTTAAGCCAGCA
CD40 AGACACCTGGAACAGAGAGAC
CFL1 TTCAACGACATGAAGGTGCGT
CNN1 ATGTCCTCTGCTCACTTCAACC
CNN2 ACCGGCTCCTGTCCAAATATG
CNN3 AGAAGAGGTGACAGGCATGAG
CXCL12 ATGCCCATGCCGATTCTTCG
CXCL14 CGCTACAGCGACGTGAAGAA
FN1 GAAGCTCTCTCTCAGACAACCA
HDAC2 ATGGCGTACAGTCAAGGAGG
IL1R2 TTCGTGGGAGGCATTACAAGC
ITGB5 AAGTTGTTTCCAAATTGCGTCC
KIT GTTCTGCTCCTACTGCTTCGC
MMP1 ACACATCTGACCTACAGGATTGA
MMP11 TCTACACCTTTCGCTACCCAC
MMP2 CTTCCAAGTCTGGAGCGATGT
MMP25 GACTGGCTGACTCGCTATGG
PSMA2 ACCAAGAACCCATTCCTACAGC
PXN CCTGGAGCAAAGAGCGGATG
RAN GGTGGTACTGGAAAAACGACC
STAT5B GAGGTGCGGCATTATTTATCCC
SIPA1 CCCTAAGGGAACTCCAAAATCTG
SPP1 TCACCAGTCTGATGAGTCTCAC
TFDP1 TGAAGCCAACGGAGAACTCAA
THY1 TCGCTCTCCTGCTAACAGTCT
TNFRSF14 ACCCTGTGTCAGAACTGCC
TNFRSF1a TGGTGGGAATATACCCCTCAG
USP19 CAGGACTGGAGGACACCACTAMembranes were blocked in 5% (w/v) non-fat dried milk in 1×
Tris-buffered saline containing 0.1% tween-20 (TBST) for 1 h at
room temperature, and then incubated overnight at 4 °C with pri-
mary antibody in TBST. Following primary incubation, membranes
were washed and then incubated with HRP-linked secondary anti-
bodies (Abcam) for 1 h at room temperature. Immuno-blot mem-
branes were visualized by incubation with SuperSignal West Femto
Max Sensitivity Substrate (Pierce) and imaged using a ChemiDoc
XRS™ System (Bio-Rad) with Quantity One Software (Bio-Rad).
Bands were quantiﬁed using the Quantity One Software (Bio-Rad)
in triplicate for each antibody. The following primary antibodies
were used: actin, alpha 2, smooth muscle, aorta (ACTA2;
AbCam#7817), Bax (Cell Signaling #2774), CASP8 and FADD-like
apoptosis regulator (CFLAR; AbCam #4042), ﬁbroblast activation
protein, alpha (FAP; AbCam#54651), glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; AbCam #8245), matrix metallopeptidase
11 (MMP11; AbCam#52904), phosphatase and tensin homolog
(PTEN; Cell Signaling #9552; Cell Signaling, Danvers, MA), periostin
(POSTN; AbCam #14041), tumor necrosis factor receptor superfamily,
member 1A (TNFRSF1A; AbCam #19139), tumor necrosis factor
receptor superfamily and member 10D (TNFRSF10D; AbCam #2019).
Statistical analysis of altered protein levels
Graph Pad Prism 4.0 software was utilized to calculate statistical
signiﬁcance of altered protein abundances across three biological
replicates of both IPF and normal samples. Each immunoblot was
repeated in triplicate, and technical replicates for each biological
sample were averaged. The data were normally distributed; there-
fore, an unpaired t-test was used to calculate statistical signiﬁcance
of densitometry readings obtained through band analysis using
Quantity One Software (Bio-Rad).
Analysis of biological processes
Pathway and gene ontology analyses were carried out using
Database for Annotation, Visualization and Integrated Discovery
(DAVID) available online through the National Institute of Allergyges.
Reverse primer Amplicon length
GCGTGGATTCTGCATAATGGT 165
AGACACGTAAGGAAAACGCATTA 191
AGTGAGCATTATTATCCTGGGGT 120
AACCCCTGTAGCAATCTGCTT 211
TCCTCCAGGATGATGTTCTTCT 110
CCCCCTCGATCCACTCTCT 121
CCCGGCTGTAGCTTGTTCA 151
GAGGCCAGTTCAGTGAGGAC 137
GCCGGGCTACAATCTGAAGG 101
TTCCAGGCGTTGTACCACTTG 170
GCCCACGGTAACAACCTCTT 234
TGCGGATTCTATGAGGCTTCA 112
ACCGTCCTAGCAGAGTCATTT 145
CTTTCGCCAGCCAATCTTCTC 186
CCACGCGGACTATTAAGTCTGA 115
GTGTGACATTACTCCAGAGTTGG 103
CTCCAGCGGTGCAATCTCATT 152
TACCGTCAAAGGGGTATCCAT 119
CGAACCTCTGCATGACTTTGATG 106
GTCCCTCATTCCAACCACAAAT 126
CCCCCAGCTTGTTCAGGTC 209
AACACTAGGGGATGAACCTCAA 101
CAGCGGTCATACGTGTTCTGG 218
CGGTTGTTGTGTCTCAGGC 168
CAGGTCTGCGAAACTTCTTAGAT 182
GCGTACCAATTACCACTTGCTG 176
CTCGTACTGGATGGGTGAACT 134
GGCTCCCTGAGAGAAACCAC 151
GCACTTGGTACAGCAAATCGAAT 131
GAGGCCAGAGGTTCAAGACC 130
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were entered into the DAVID database and the resulting gene
ontologies were analyzed for enrichment of biological processes.
Additional pathway analysis was carried out through Kyoto encyclo-
pedia of genes and genomes (KEGG) [12–14].Results/discussion
Cell population
Our model of non-cultured isolated ﬁbroblasts was central to
this study's design. Speciﬁcally, the ﬁbroblasts used in this study
were extracted expeditiously from explanted lungs, which limited
ex vivo phenotypic transformations known to occur as a result of
in vitro propagation of primary cells and tissue explants [15–17].
The technique of differential binding has successfully been used
previously to both isolate and eliminate ﬁbroblasts [5,18–20],
however this is the ﬁrst report of ﬁbroblasts isolated in this man-
ner from lung tissue without subsequent long-term tissue culture.
Immediately post-isolation, both the IPF and normal ﬁbro-
blasts shared a rounded morphology (Figs. 1A and C). However,
when continued in culture over 120 h, both cell populations dem-
onstrated the classic ﬁbroblast-like elongated morphology (Figs. 1B
and D) and extensive α-SMA staining (Figs. 1F and H). Further
immunocytochemical analyses clearly demonstrated that both the
IPF and normal ﬁbroblasts were virtually free of contaminating
epithelial cells (Figs. 2A and C), monocytes/macrophages (Figs. 2D
and F) and endothelial cells (Figs. 2G and I). Quantiﬁcation of K18
and α-SMA staining of IPF and normal ﬁbroblast populations
immediately post-isolation both demonstrated that IPF and normal
ﬁbroblasts were virtually free of contaminating epithelial cells
and conﬁrmed the ﬁbroblast identity of the cells. Speciﬁcally, both
cell populations demonstrated negligible presence of the epi-
thelial cell marker, K18, (1.80±0.67%), and stained positively for
α-SMA (99.80±0.24%) immediately post-isolation, tested in ﬁve
randomly chosen ﬁelds.Fig. 1. Conﬁrmation of IPF and normal ﬁbroblast cell populations. Morphology of IPF ﬁbrob
(100× magniﬁcation imaged on a Leica light microscope). After 120 h in culture, the
Immunoﬂuorescent staining of IPF ﬁbroblasts (E) and normal ﬁbroblasts (G) at 45 min differ
DAPI nuclear stain, 200× magniﬁcation). The 45 min differential binding population continu
characteristic staining for alpha smooth muscle actin depicting the stress ﬁbers (200× magMicroarray analysis
To determine the differential gene expression between non-
cultured IPF and normal ﬁbroblasts, we extracted RNA from
ﬁbroblasts isolated as described. A total of 38 samples from 12 IPF
lungs and 19 samples from 6 normal lungs were analyzed (Table 1).
SAM analysis (FDR=0%; delta=2.26) identiﬁed 1813 signiﬁcantly
differentially expressed transcripts between IPF ﬁbroblasts and
normal ﬁbroblasts. Hierarchical clustering (Euclidean distance)
revealed a clear distinction between the IPF and normal ﬁbroblasts
across all samples, highlighting the signiﬁcant distinction in global
gene expression between these two unique ﬁbroblast populations.
Validation of the microarray results
Validation of transcript abundance
Microarray data was validated using qRT-PCR of selected genes
from the gene list. In each case qRT-PCR fold changes correlated with
those derived from the SAM analysis (Table 2, Fig. 3).
Validation of translation into proteins
Western blot analysis was used to determine the altered
abundance of 12 selected proteins represented in our microarray
data. All alterations in protein abundance coincided with the
directional changes of genes identiﬁed through the microarray
analysis (Figs. 4A and B).
Biological processes identiﬁed in IPF ﬁbroblasts—DAVID
and KEGG analyses
DAVID analysis of our 1813 signiﬁcant-genes list derived a
comprehensive ranking of functional annotations and ontologies. Of
the signiﬁcantly altered transcripts, 1242 unique genes were
recognized and categorized by DAVID (Table 3). This analysis
described many altered biological processes and constituent path-
ways (Table 4) previously unreported in IPF ﬁbroblasts. Speciﬁcally,lasts and normal ﬁbroblasts at 45 min differential binding appears rounded (A and C)
se cells acquire the familiar stretched-out ﬁbroblast-like morphology (B and D).
ential binding demonstrates the presence of alpha smooth muscle actin (Texas Red and
ed in culture for 120 h, IPF ﬁbroblasts (F) and normal ﬁbroblasts (H) show diffuse and
niﬁcation). Size bar set to 100 µm.
Fig. 2. IPF and normal ﬁbroblast cell populations demonstrate negligible cellular contamination. Immunoﬂuorescent staining of IPF ﬁbroblasts (A) and normal ﬁbroblasts (C) for
cytokeratin 18 epithelial cell marker (conjugated to Texas Red (green pseudo-color) and DAPI nuclear stain; 200× magniﬁcation) shows very few positive cells (arrows). (B) A549
pulmonary epithelial cells, positive control for cytokeratin 18. Immunoﬂuorescent staining of IPF ﬁbroblasts (D) and normal ﬁbroblasts (F) depicts the absence of staining for
endothelial cell marker, VonWillebrand's Factor (conjugated to Texas Red (pink pseudo-color) and DAPI nuclear stain) compared to humanmicrovascular endothelial cells, positive
control (E). Immunoﬂuorescent staining of CD11b, monocyte/macrophage cell marker (conjugated to Texas Red (green pseudo-color) and DAPI nuclear stain; 200× magniﬁcation),
depicts few potential contaminants in the IPF ﬁbroblast population (G) and normal ﬁbroblast population (I) compared to human monocyte/macrophage cell line, MD (H). Size bar
was set to 100 µm.
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processes including the ubiquitin/proteasomal degradome and
vitamin metabolism. In support of the validity of our data, we also
identiﬁed a number of biological processes and representative path-
ways previously reported in association with IPF lungs. The nature of
this analysis within the context of this isolated and non-cultured
cellular population enables us to attribute these biological processes
speciﬁcally to the ﬁbroblast cell populations. Of these processes, cell
death associated processes ranked highest in signiﬁcance, while other
biological processes, some of which have previously reported to be
associated with IPF ﬁbroblasts, were also identiﬁed. These included
wound healing and response to stress processes [21,22]; cytokine
receptor signaling including chemokines, tumor necrosis factor-α
(TNF-α) and transforming growth factor-β (TGF-β) signaling mem-
bers [21–24]; the Wnt pathway [24–26]; ECM–receptor interactions
[27]; cytoskeletal organization and biogenesis [28–30]. These speciﬁc
important ﬁndings are robustly complemented by the global data
presented in this study.
Cell death
Within the assemblage of biological processes associated with
cell death, we found a complex array of gene alterations involved
in apoptosis (Table 3). Interestingly, these included predominantly
pro-apoptotic expression changes. Apoptotic dysregulation in IPF is
a highly controversial topic. The role that this homeostatic process
plays in IPF may be cell-type speciﬁc and thereby integral to disease
progression. For example, epithelial cells in the IPF lung appear to
show increased rates of apoptosis, thereby contributing to loss of
lung architecture [31]. On the other hand, while there is data
suggestive of an increased rate of apoptosis in IPF ﬁbroblasts derivedfrom lung tissue explants [32], other studies suggest that IPF ﬁbro-
blasts are more apoptosis resistant [31–33]. There is also a dis-
parity between previous ﬁndings of decreased apoptosis and our
data, which suggests a preponderance of pro-apoptotic expression
changes. This discrepancy may be attributable to the nature of the
ﬁbroblasts used in this study, which were non-cultured. For
example, we found increased expression of the apoptosis inducing
ligand TNFSF10 (TRAIL ligand) and concurrent down-regulation of
its decoy receptor, TNFRSF10D. This decoy receptor interacts with
TNFSF10, but lacks the apoptosis inducing death domain which
would suggest an increased propensity for apoptosis in ﬁbroblasts.
The expression of other downstream pro-apoptotic mediators was
also altered in IPF ﬁbroblasts, including up-regulation of BAX
(Figs. 3C and 4) and pro-apoptotic CASP6. Additionally, down-
regulation of the pro-survival interleukin-1 receptor-associated
kinase 1 (IRAK1) was also observed adding to the overall potentially
pro-apoptotic signaling environment. This data would seem to be
in opposition to the overall abundance of ﬁbroblasts in the IPF
lung. However, the complex milieu that is the IPF lung undoubt-
edly plays a role in modulating these signals. In light of these
complexities, our data suggest that an in-depth investigation of
apoptotic signaling in each cell type in the IPF lung may unravel this
conundrum.
Catabolic processes
Within the data for IPF ﬁbroblasts was a signiﬁcant representa-
tion of catabolic processes which may provide insight into
dysregulated homeostasis in these cells. In IPF, conﬂicting signals
for massive ECM deposition are pitted against those for ECM and
protein degradation. This involves proteases such as the matrix-
Fig. 3. qRT-PCR conﬁrmed the direction and further elucidated the fold change (arbitrary units) of selected genes identiﬁed in the microarray analysis. (*=pb0.05 and **=pb0.01.)
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(ADAMS) and their inhibitor proteins, tissue inhibitors of metallo-
proteinases (TIMPS). This complex interplay between these cata-
bolic and anabolic enzymes has been dubbed the degradome. It
has been suggested that in IPF this degradome is abnormal, resulting
in deregulation of the catabolic processes inherent to cellular
homeostasis [34]. Within the biological processes that encompass
catabolism, we identiﬁed, for the ﬁrst time, increased expression
of the ubiquitin conjugating enzymes UBE2T, UBE2K and UBE2D4.
Additionally de-ubiquitination proteases, such as ubiquitin speciﬁc
proteases USP6, USP10, USP15, USP18 and USP19 were also altered,
as was ubiquitin-like modiﬁer activating enzyme 1 (UBA1)
(Table 4). These alterations in ubiquitination and de-ubiquitination
enzymes potentially have profound implications for ubiquitin/
proteosomal regulation and control of proteolysis. This is of
particular interest in light of our observation of increased expres-
sion of several comõponents of the proteasome including protea-
some subunits, PSMB5, PSMA2, PSMA3, and PSMD10. The 26S
proteasome is a vast multi-subunit complex, located in the nucleusand cytosol, which accounts for the bulk of cellular protein turnover
via ubiquitin tagged degradation [35]. These numerous expression
changes noted in the ubiquitin/proteasome regulation of proteins
may potentially impact critical homeostatic processes in the IPF
ﬁbroblast. For example, with respect to the cell cycle's regulation,
we noted increased expression of FBXO32, the f-box subunit of the
Skp1-Cullin/Cdc53-F-box protein (SCF) complex. The SCF complex
is a ubiquitin ligase complex that recognizes sequences in key
regulators of cell cycle such as cyclin-dependent kinase inhibitor 1B
(CDKN1B; p27, Kip1) and cyclins D, E and A. Altered catabolic
regulation in key control elements of the cell cycle that result from
this, may dramatically impact proliferation in IPF ﬁbroblasts, and
thereby effect an imbalance of cellular homeostasis [36].
Cell cycle
Central to the pathogenesis of IPF, is the control of the cell cycle
and the over abundant ﬁbroblast population. Interestingly, in spite of
its obvious contribution to the IPF lung phenotype, little research
Fig. 4. Immuno-detection of proteins in IPF ﬁbroblasts versus normal ﬁbroblasts. Lanes
1–3 are individual biological replicates of total cell lysates of normal ﬁbroblasts, lane 4 is
molecular weight marker and lanes 5–7 are individual biological replicates of total cell
lysates of IPF ﬁbroblasts. Loading control depicts Coomassie Blue staining of a
representative gel (see Materials and methods). Protein speciﬁc lanes from twelve
individual immuno-blots show (A) changes seen in protein levels in IPF ﬁbroblasts
consistent with genomic alterations identiﬁed through the microarray and measured
by densitometry (B). (pb0.05=*, pb0.01=**, pb0.001=***).
Table 3
Functional annotation chart: gene ontology term—biological-processes [2].
Gene ontology
term
Biological
process
Benjamini Fold
enrichment
GO:0016265 Death 3.8E-04 1.6
GO:0040008 Regulation of growth 4.1E-04 2.4
GO:0006950 Response to stress 5.4E-04 1.5
GO:0006928 Cell motility 6.8E-04 1.9
GO:0051674 Localization of cell 6.8E-04 1.9
GO:0007155 Cell adhesion 8.7E-04 1.6
GO:0009719 Response to endogenous stimulus 1.4E-03 1.8
GO:0048468 Cell development 2.0E-03 1.4
GO:0022402 Cell cycle process 2.0E-03 1.6
GO:0016049 Cell growth 3.5E-03 2.1
GO:0008283 Cell proliferation 3.7E-03 1.5
GO:0009605 Response to external stimulus 3.7E-03 1.6
GO:0007049 Cell cycle 3.7E-03 1.5
GO:0065009 Regulation of a molecular function 1.3E-02 1.5
GO:0065008 Regulation of biological quality 3.4E-02 1.4
GO:0009056 Catabolic process 5.8E-02 1.4
GO:0042221 Response to chemical stimulus 6.3E-02 1.4
GO:0051716 Cellular response to stimulus 1.4E-01 3.7
GO:0050817 Coagulation 1.9E-01 2.0
GO:0001775 Cell activation 2.1E-01 1.5
GO:0002520 Immune system development 2.4E-01 1.5
Table 4
Selected genes from signiﬁcant biological processes and constituent pathways
identiﬁed by DAVID analysis of gene ontologies.
Pathway Genes: increased Genes: decreased
Protein
catabolism
(proteasome)
PSMB5, PSMA4, MMP11,
PSMA2, USP18, MMP1,
PSMA3, PSMD10, MMP2, UBE2T
USP19, USP10
Cytokine/
cytokine
receptor
signaling
BMPR2, ACVR1, TGFB3,
INHBA, CD40, KIT, CXCL14,
CXCL12, PPBP
IL1R2, RELT
TNFRSF14, IFNAR1,
IL4R, TNFRSF1A
Cytokine:
TGF-beta
RBX1, ID3, ACVR1, INHBA,
TGFB3, DCN, COMP, BMPR2
THBS1
Wound healing BDKRB1, CD40, CXCL12,
CXCL14, FN1
STAT3, TNFRSF1A,
MMP25, STAT5A
Programmed
cell death
FAIM, CD40, DAD1, CCAR1,
BAX, CASP6, TNFSF10
DEDD, TNFRSF14, TNFRSF1A,
SIPA1, DAPK2, TNFRSF10D
Cell cycle
regulation
HDAC2, TGFB3, CDKN3, CKS2 TFDP1, HDAC4, CDKN2D,
CCNH, PTEN
ECM/receptor
interaction
COL1A1, FN1, SPP1, ITGBL1,
THY1, ITGB5
PXN
Vitamin
metabolism
NMNAT1, RDH11, RBP1, MDH1 RARA, GLYR1
FOLR3
Wnt pathway SFRP2, PRICKLE1 DVL1
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observed that a number of genes associated with the cell cycle and its
control were altered in non-cultured IPF ﬁbroblasts. Our ﬁndings
show altered expression levels in genes promoting the cell cycle
progression through the major G1/S check points. For example, the
cyclin-dependent kinase inhibitor 2D (CDKN2D; p19) is down-
regulated, potentially allowing cyclin D1 to promote G1/S progres-
sion. In addition we found up-regulation of cell cycle regulators, such
as protein regulator of cytokinesis 1 (PRC1) and CDC28 protein kinase
regulatory subunit 1B (CKS1B). Up-regulation of these proteins has
been associated with aggressive forms of cancers including multiple
myeloma, colorectal, prostate and breast cancer suggesting their
potential role in rapid proliferation [37,38]. A number of the
disruptions observed in the cell cycle in IPF parallel those observed
in various forms of cancer. This correlates histopathologically with
the almost “cancer-like” proliferation of ﬁbroblasts and clinically with
the progressive course and poor outcomes of IPF. However on the
contrary, we also observed down-regulation ofmembers of the cyclin-
dependent kinase activating complex (CAK), a powerful pro-cell-cycle
regulator, Cyclin H (CCNH) and ménage a trois (MNAT1). The overallcontribution of the CAK complex down-regulation in IPF ﬁbroblasts is
currently unclear; however this again underscores the complex
nature and potential dysregulation of the cell cycle in IPF.
Cytokine/cytokine receptor signaling
The role of cytokines and cytokine signaling is intuitively central to
the pathogenesis of IPF due to their inﬂuence on processes such as
migration, differentiation and proliferation [23,39]. However, the
exact role of many cytokines, speciﬁcally in isolated IPF ﬁbroblasts,
has yet to be characterized. In this study we observed a complex array
of altered cytokine expression in IPF ﬁbroblasts.
C-X-C motif
Within the C-X-C motif cytokine family, we observed up-
regulation of the pro-inﬂammatory pro-platelet basic protein che-
mokine (C-X-C motif) ligand 7 (PPBP). The gene product, PPBP, is
known to play a role in the early stages of wound healing through its
recruitment of neutrophils to the site of injury, however this cytokine
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cells from bone marrow, a role that may contribute directly to
increased ﬁbrosis [40]. We also found up-regulation of CXC motif
family member, CXCL12, which is consistent with this chemokine's
potential role in animal models of ﬁbrosis [41–43]. In concert with
PPBP, CXCL12 has also the potential to recruit ﬁbrocytes and
mesenchymal stem cells (MSC) to the IPF lung, both of which have
the capacity to transition to ﬁbroblasts [41,42,44]. Interestingly the
theory of recruitment of ﬁbrocytes to the IPF lungs has recently
been gaining ground with respect to the pathogenesis of IPF, and
circulating levels have been correlated with a poor prognosis [41].
We also identiﬁed the up-regulation of the cytokine, CXCL14, an
orphan chemokine which has not previously been associated with
IPF. This cytokine, also known as BRAK (Breast and Kidney), has been
associated with a number of cancers including prostate cancer and
pancreatic cancer, where its role varies based on the context of
each tissue [45–47]. Pertinent to IPF are recent studies in prostate
cancer that explored the role of secreted ﬁbroblast-derived factors in
prostate cancer growth [48]. Speciﬁcally, it has been demonstrated
that tumor associated ﬁbroblasts over-expressing CXCL14 promote
the growth of prostate cancer xenografts, increasing tumor angio-
genesis and macrophage inﬁltration. This suggests that CXCL14 is a
potential autocrine stimulator of both ﬁbroblast growth and migra-
tion, processes central to IPF pathogenesis. CXCL-14 is also believed
to prompt enhanced epithelial proliferation, migration and invasion
[49,50]. In IPF, these events may enhance the migration of epithelial
cells that are undergoing epithelial-to-mesenchymal transition (EMT)
and may facilitate the recruitment of cells, such as ﬁbrocytes. These
combined multi-modal stimulatory activities make CXCL-14 a
potential major player in the cytokine milieu of the IPF lung.
Tumor necrosis factor superfamily
The tumor necrosis factor superfamily (TNFSF), another family of
cytokines, was also found to be altered in our IPF ﬁbroblasts. This
cytokine family impacts many important regulatory pathways;
namely apoptosis, cytoskeletal homeostasis, wound healing, and
ECM–receptor interactions (Table 4). In addition to the altered ex-
pression of TNFSF10 and its decoy receptor, TNFRSF10D, we also
found down-regulation of the pro-inﬂammatory cytokine, tumor
necrosis factor receptor superfamily member 1A (TNFRSF1A)
(Table 4; Fig. 3C). While the exact contribution of these TNFSF
members' alterations in the pathobiology of IPF is unknown, similar
transcriptional changes observed in other diseases may shed light
on their potential contribution in IPF. For example, while smoking
is not considered a cause of IPF, it is a recognized risk factor, and
one study has found that TNFRSF1A is down-regulated in response
to components of cigarette smoke [51] Another change noted was
the up-regulation of tumor necrosis factor receptor superfamily,
member 5 (CD40), which has predominantly been described as a
mediator of a broad range of inﬂammatory responses. However
recently, CD40 has been shown to promote ﬁbroblast proliferation
in a mouse model of skin ﬁbrosis [52]. Therefore, while CD40 may
be pro-inﬂammatory, it is reasonable to speculate that its action in
IPF is more closely akin to its role in the mouse model of skin
ﬁbrosis.
TGF-β pathway
The cytokine/cytokine receptor interaction most commonly
identiﬁed with and critical to the pathogenesis of IPF is that of the
TGF-β pathway. This pathway inﬂuences many cellular processes,
including modulation of apoptosis and cell cycle signaling [23].
Notably, we found that transforming growth factor beta 3 (TGFB3)
was up-regulated in IPF ﬁbroblasts (Table 3). One potential role for
TGFB3 in IPF is its ability to potentiate EMT, a signiﬁcant process
implicated in the pathogenesis of IPF [53–55]. TGFB3 has also been
shown to induce an increase in lymphoid enhancer factor 1 (LEF1)expression, resulting in the formation of the LEF1/β-catenin complex,
which has in turn been shown to initiate EMT [56]. The destruction
of the lung epithelium basement membrane, as seen in IPF, enables
the direct interaction of epithelial cells with ﬁbroblasts. This disrup-
tion of the basement membrane enables factors from the ECM to
interface with epithelial cells, thereby promoting their de-differenti-
ation and potential transformation into ﬁbroblasts [54,57,58]. Inter-
estingly, a recent report noted that human lung epithelial cells, in the
presence of collagen, release active TGFβ3, which induces EMT via
canonical TGFβ signaling [55].
Another TGF-β pathway member we found to be altered was bone
morphogenic protein receptor 2, BMPR2. Previous studies have
associated this receptor with an increased propensity for pulmonary
arterial hypertension, and its up-regulation in IPF ﬁbroblasts, might
result in the greater predisposition of IPF patients to develop
secondary pulmonary hypertension [59]. Clearly, the role of the
TGF-β family in IPF is complex and vital, and remains to be fully
elucidated.
Defense Response pathway
Our analysis also identiﬁed derangements in the pathway of
Defense Response processes, which are previously unreported in
IPF. Speciﬁcally, we found signiﬁcant up-regulation of Bradykinin
Receptor B 1 (BDKRB1). The bradykinin ligands, which signal
through the two receptors, BDKRB1 and 2, are up-regulated in
wounded tissue [60], and may therefore play a role in the limited
inﬂammatory component of IPF. In a recent murine study of kid-
ney ﬁbrosis, a BDKRB1 knock model showed that the absence of
this receptor impeded ﬁbrosis, suggesting that this receptor has pro-
ﬁbrotic activity [61]. Therefore, the up-regulation of BDKRB1 in IPF
ﬁbroblasts may similarly play an important ﬁbrogenic role in IPF
as suggested in this murine study.
Vitamin metabolism
Novel expression changes in biological processes associated
with vitamin metabolism were also noted (Table 3). Among the
most prominent were alterations in folate, nicatinamide and retinol
metabolism affecting a broad range of biochemical processes,
including the citric acid (TCA) cycle. Alterations that inﬂuence the
TCA cycle can profoundly inﬂuence the cellular energetics of a cell
and may thereby affect the growth and proliferation of IPF
ﬁbroblasts. Speciﬁcally, we identiﬁed alterations in the expression
of a number of members of the retinoic acid pathway. In par-
ticular we documented down-regulation of the retinoic acid
receptor, alpha (RARA) and retinoic acid binding protein (RBP) 7
in IPF ﬁbroblasts. RARA is a nuclear receptor mediating the sigõ-
naling of the powerful morphogen, retinoic acid (RA) and the RBPs
all participate in mediating the cellular response to RA. The RA
pathway comprises genes shown to be signiﬁcantly altered in
uterine ﬁbroids [62], a common benign neoplasm of smooth muscle
cells. The role of altered RA pathway in uterine ﬁbroids may
foreshadow the consequences of this pathway's dysregulation in
IPF ﬁbroblasts, a cell with similar attributes to smooth muscle cells.
In addition, RA has been documented to exacerbate liver ﬁbrosis via
plasminogen activator/plasmin levels and induce proteolytic acti-
vation of latent transforming growth factor beta (TGF-beta), the
purported master cytokine in IPF [63]. Additionally, because of its
well described role regulating cellular differentiation during organ
development, alterations in the levels of the proteins associated
with its pathway, such as those identiﬁed herein, may play a fun-
damental role in the pathobiology of IPF ﬁbroblasts. Intriguingly, the
proteasome, whose expression is also altered in these cells, controls
the duration of RARA signaling by degradation [64,65].
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1 (NMNAT1) was also noted in IPF ﬁbroblasts. NMNAT-1 is a central
facilitator of redox reactions in the mitochondrial electron transport
chain, which inﬂuence many cellular processes such as the cell cycle,
and catalyzes the formation of the essential cofactor nicotinamide
adenine dinucleotide (NAD). Over-expression of NMNAT-1 has been
shown to extend the lifespan of cells, an ability which has been
attributed to its augmentation of NAD+-dependent histone deacety-
lation catalyzed by the silent information regulator 2 (Sir2) family of
proteins [66]. The Sir2 family, including sirtuin 1 (SIRT1), regulates a
variety of cellular processes including differentiation, motility and cell
survival [67]. This pro-survival role for NMNAT1, via the Sir2 family in
other systems, may have implications for IPF ﬁbroblast longevity. On
the contrary, increased NMNAT-1 may play a very different role in IPF
ﬁbroblasts. Recent reports have shown that over-expression of
NMNAT-1 in HeLa cells modulates the behavior of poly(ADP-
ribosyl)ation protein 1 (PARP1) an enzyme essential in processes
such as DNA repair and programmed cell death. This association of
NMNAT-1 with activated PARP1 can also enhance the relocation of
apoptosis inducing factor (AIF) from the mitochondria to the
nucleus, thereby triggering apoptosis [68]. This typically occurs in
response to oxidant damage mediated through activated PARP1, a
pathway which may be an important pro-apoptotic force for IPF
ﬁbroblasts [68]. These two contradictory behaviors of NMNAT-1
with respect to cell survival highlight the potential conﬂicting
apoptotic and mitogenic behaviors surrounding IPF ﬁbroblasts
[31,32].
In keeping with expression changes that control metabolism,
we also demonstrated that malate dehydrogenase I (MDHI), which
is central to the malate/aspartate shuttle, is also up-regulated [69].
However, it is MDH1 interactions with p53 that may be more
pertinent in IPF ﬁbroblast pathobiology. MDH1 has been shown to
interact with p53 resulting in regulation of p53 mediated cell cycle
arrest and apoptosis [70]. The interactions of MDH1 and p53 are
particularly pronounced in environments of low glucose, which may
be similar to those of an IPF lung in which aberrant angiogenesis
and pathological vascular obliteration might contribute to the de-
creased availability of glucose to the lung cells [23].
ECM–receptor interactions
The contribution of the ECM produced by the ﬁbroblast is central
to the phenotype of the IPF lung and its clinical, radiographic and
histopathologic manifestations. As expected, our analysis identiﬁed
the up-regulation of COL1A1, the ECM component whose deposition
is the hallmark of pulmonary ﬁbrosis. This up-regulation occurred
in concert with the up-regulation of COL16A1, a member of the ﬁbril-
associated collagens with interrupted helices (FACIT) family. This co-
expression increase may serve to strengthen the integrity of the
evolving ﬁbroblasts' ECM, promoting the adhesion and ﬁbrogenic
nature of the IPF ﬁbroblast. This is similar to the situation in glio-
blastomas where increased COL16A1 expression has been shown to
contribute to the increased adhesion of these cells [71]. It is also
possible that the up-regulation of COL6A2 observed in our IPF
ﬁbroblasts may facilitate increased interactions between ﬁbronectin
(FN) and its integrin receptors thereby increasing its ﬁbrogenic
effect [72]. FN1 is known for its role in cell adhesion and migration
processes, particularly in wound healing (Table 3). In keeping with
these hypothesis is the ﬁnding that ﬁbronectin 1 (FN1) was also up-
regulated in IPF ﬁbroblasts. In addition, our study identiﬁed a mul-
titude of other up-regulated collagen subtypes, including COL5A2 and
COL3A1,which are known to interact with Col1A1 contributing to the
classic IPF ECM [72].
We also noted the up-regulation of non-collagenous constituents
of the ECM. The most prominent of which are the laminin family
of glycoproteins, including laminin β 2 (LAMB2) and laminin α 4(LAMA4), both of which were up-regulated. Laminins are of particular
importance as they are integral to the basement membrane, and
modulate intercellular adhesion and cellular motility [73]. While it is
unknown how the up-regulation of LAMB2 contributes to IPF
pathobiology, this ECM component has previously been associated
with cell adhesion, differentiation, migration, signaling of neurite
outgrowth and prostate cancer metastasis [74]. Of these processes,
cell adhesion, differentiation and migration have all been identiﬁed as
important factors in ﬁbrogenesis, and therefore by analogy suggest a
potential contribution of LAMB2 up-regulation to the ﬁbrotic
phenotype of IPF [75].
The matricellular family of proteins is a class of ECM molecules
whose properties are distinct from both the structural macromole-
cules and the more bioactive proteins such as growth factors,
cytokines, and proteases that also comprise the ECM. They are
deﬁned by their ability to modulate cell–matrix interactions and are
actively expressed during wound repair and disease [76]. This family,
highly represented in our gene list, includes, tenascin-C (TNC),
osteopontin (SPP1), secreted protein acidic rich in cysteine (SPARC),
bone sialoprotein, thrombospondins and members of the CCN family
such as cysteine-rich, angiogenic inducer, 61 (CYR61; CCN1). While
the roles of tenascin-C, SPARC, SPP1,thrombospondins and CYR61
have previously been explored in pulmonary ﬁbrosis, the role of
altered POSTN (periostin) expression has yet to be clariﬁed.
Periostin affects structural and functional properties of connec-
tive tissues by inﬂuencing collagen ﬁbrillogenesis [76]. However, its
reported function as a novel component of subepithelial ﬁbrosis
in bronchial asthma [77] may allude to a similar role in IPF. POSTN
is also up-regulated in the stromal cells of bone marrow ﬁbrosis, and
this up-regulation is enhanced by the presence of TGF-β, making
periostin a particularly interesting component of IPF [78]. Increased
expression of POSTN has also been noted in cancer studies where
certain of its actions might be consistent with IPF pathogenic mech-
anisms, such as the stimulation of angiogenesis [79]. It achieves this
via increased expression of the VEGF receptor Flk-1/KDR by
endothelial cells [80]. Periostin has also demonstrated a role in
EMT, a process of great importance in IPF [4]. The role of the ECM
and the components thereof are clearly crucial to IPF disease
progression as evidenced by the aforementioned individual compo-
nents and their documented interplay and behaviors in other
ﬁbrotic diseases.
Wnt pathway
A pathway with rapidly emerging implications in IPF is the
Wnt pathway [24–26]. The Wnt pathway coordinates with many
cellular regulatory processes including cell cycle regulation, TGF-β
signaling, and proteasomal regulation of protein degradation. Wnt
signaling has also been shown to be increased in IPF epithelial cells,
IPF whole lung tissue samples and primary ﬁbroblasts cultured from
lung tissue [24–26]. While the exact role of Wnt signaling in IPF
requires greater clariﬁcation, it is clear that downstream target
genes of the Wnt pathway might play a signiﬁcant role in IPF. Spe-
ciﬁcally in this study we demonstrate alteration of 11 genes
within the Wnt pathway including the down-regulation of dishev-
elled (DVL1) and the up-regulation of SFRP2, indicating aberrant
Wnt signaling in IPF ﬁbroblasts. SFRP2 is of particular interest as it
is not only an antagonist of the Wnt signaling pathway but it has
also recently been identiﬁed as contributing to ﬁbrosis in a mouse
model of myocardial infarction. This ﬁbrotic behavior is associated
with SFRP2's ability to act as a procollagen C proteinase enhancer,
which enhances the conversion of procollagen (I–III) precursors into
major ﬁbrillar components of the ECM through the activity of the
mammalian tolloid-like proteinases [81]. Two additional procollagen
remodeling genes were also found to be up-regulated in our IPF
ﬁbroblasts: procollagen C-endopeptidase enhancer (PCOLCE) and
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to and enhance the processing and correct folding of collagen in
the ECM. With their inherent role in ECM integrity, these proteinases
and enhancers of proteinases may potentially prove to be valuable
targets for future therapies in IPF.
Cytoskeletal organization and biogenesis
Changes in biological process associated with cytoskeletal orga-
nization and biogenesis are also central to IPF ﬁbroblast pathobiol-
ogy. While increased α-SMA in IPF ﬁbroblasts is expected (Fig. 4),
our study also demonstrates previously unidentiﬁed expression
changes in genes associated with cytoskeletal organization and
biogenesis. Speciﬁcally, we found basic calponin (CNN1), a modu-
lator of the cytoskeleton, to be highly up-regulated. CNN1 is in-
volved in host–tumor interactions where it has been shown to
facilitate smooth muscle migration [82], a role that may also be
important in IPF ﬁbroblasts. A second calponin family member,
neutral calponin (CNN2), was found to be down-regulated in the IPF
ﬁbroblast. Unlike CNN1, CNN2 has been shown to inhibit the
activity of the actin cytoskeleton in vitro by inhibiting cellular
contractile capabilities [83] and by modulating cell proliferation
through the inhibition of cytokinesis [84]. Its down-regulation, as
seen in IPF ﬁbroblasts, could result in a decrease of its inhibition
of cell proliferation, and thereby contribute to the abundance of
ﬁbroblasts.
Conclusions
Our technique in providing a genomic analysis of rapidly
isolated non-cultured ﬁbroblasts from IPF lungs limits the oppor-
tunity for ex vivo phenotypic transformation and thereby provides
a unique insight into this central IPF effector cell [15–17]. Previous
studies utilizing whole lung tissue have provided a global spectrum
of gene signaling. However, important expression changed speciﬁc
to particular cells and critical to disease pathogenesis may be lost
in the genomic milieu of total lung tissue as a result of signal-
dilution. Our methodology has provided a conduit to uncover pre-
viously unidentiﬁed pathways and components that may be critical
to our understanding of the uninhibited proliferation, excessive
ECM deposition and aberrant apoptosis that characterize the IPF
ﬁbroblast.
A potential limitation of our study is the choice of patients
enrolled which included only those with end-stage disease. It is
therefore possible that our analysis of the pathways and mechan-
isms may not be representative of the ﬁbroblasts in patients with
earlier stages of the disease. Additionally, for a number of reasons
we chose not to use laser capture microdissection (LCM) to isolate
the ﬁbroblast population. First, the multiple sources of the ﬁbroblast
population in IPF make identifying ﬁbroblasts for LCM problematic.
In addition, there is a lack of a truly speciﬁc cell marker for ﬁbro-
blasts. The speciﬁc make-up of the ﬁbroblast population in the IPF
lung remains unclear with four possible reservoirs contributing
to the overall ﬁbroblast population including circulating ﬁbrocytes,
de-differentiated epithelial cells, pleural mesothelial cells and
resident activated ﬁbroblasts [41,54,85,86]. Therefore use of LCM
to selectively remove ﬁbroblastic foci may be too restrictive in its
selection of ﬁbroblasts for this type of study. For example, it may
exclude contributing ﬁbroblasts outside of the developed foci,
such as those residing at the edges of normal appearing tissue or
adjacent to vasculature or airways. Lastly, LCM cannot capture live
cells from tissue, thereby restricting further experimentation.
By exploiting the differential binding capacity of ﬁbroblasts, we
were able to isolate our IPF ﬁbroblasts and identify global genomic
differences in comparison to identically processed normal controls.
These differences included expression changes highly enriched inbiological processes previously unreported in IPF. In particular, the
alterations in vitamin metabolic processes deserve further scrutiny
as 12these processes impact fundamental homeostatic processes
including cellular energetics and the TCA cycle, cellular differentia-
tion, apoptosis and the cell cycle. In addition, our observations of
expression changes within numerous constituents of the ubiquitin/
proteasomal degradation pathway suggest that further characteriza-
tion of this regulatory process is warranted.
In conclusion, our data help to shed light on potential biological
processes and pathways that might be important in explaining the
unchecked abundance of ﬁbroblasts that characterizes IPF. Whatever
the trigger or predisposing factor(s) might be, it appears that
“switching off” this cell could be integral to halting the course of the
disease and improving patient outcomes. Our study provides a
genomic foundation for in-depth functional studies that will hopefully
enable the development of future, therapeutic trials targeting this
central effector cell.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.ygeno.2010.04.005.
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